Literature DB >> 9747858

Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?

G M Clark.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9747858     DOI： 10.1093/jnci/90.18.1320

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

Review 1.  New data on adjuvant therapy for breast cancer.

Authors:  A C Wolff; N E Davidson
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

Review 2.  Receptor imaging in breast carcinoma: future prospects.

Authors:  C Van de Wiele; S Van Belle; G Sleghers; R A Dierckx
Journal:  Eur J Nucl Med       Date:  2001-06

3.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Authors:  T A Järvinen; M Tanner; V Rantanen; M Bärlund; A Borg; S Grénman; J Isola
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4.

Authors:  A J Lodge; J J Anderson; W J Gullick; B Haugk; R C F Leonard; B Angus
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

5.  Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.

Authors:  Mehmet Salih Iyikesici; Gul Basaran; Faysal Dane; Meltem Ekenel; P Fulden Yumuk; Devrim Cabuk; Mehmet Teomete; N Serdar Turhal
Journal:  Int J Clin Exp Med       Date:  2014-05-15

Review 6.  Chemotherapy individualization.

Authors:  Gareth J Veal; Sally A Coulthard; Alan V Boddy
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

7.  Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer.

Authors:  Päivikki Kauraniemi; Tuula Kuukasjärvi; Guido Sauter; Anne Kallioniemi
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

8.  Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer.

Authors:  Andreea Nistor; Peter H Watson; Norman Pettigrew; Karim Tabiti; Angelika Dawson; Yvonne Myal
Journal:  BMC Clin Pathol       Date:  2006-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.